Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-HER2 ADCs in HER2-Positive Early Breast Cancer as Neoadjuvant Therapy
NCT07844018Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2027
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in breast cancer, sponsored by Peking University People's Hospital. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07844018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07844018.